CompletedPhase 2

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

United States40 participantsStarted 2004-11

Plain-language summary

The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.

Who can participate

Age range18 Years – 130 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Locally advanced or hereditary medullary thyroid cancer * Signed informed consent * One or more measurable lesions Exclusion Criteria: * Brain metastases or spinal cord compression * Specific laboratory ranges * Specific heart problems * Prior chemotherapy and/or radiation therapy * Participation in other trials within 30 days

What they're measuring

Objective Response Rate

Timeframe: Pre-dose and every 12 weeks up to RECIST progression as defined according to RECIST 1.0.

Trial details

NCT IDNCT00098345

SponsorGenzyme, a Sanofi Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-02

Results submitted2011-04-27

View on ClinicalTrials.gov More Thyroid Cancer trials